Transcatheter arterial embolisation in four dogs with hepatocellular carcinoma

Oishi, Yasuhisa; Tani, Kenji; Taura, Yasuho

doi:10.1111/jsap.12944

Cited by 7 publications

(8 citation statements)

References 16 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…The use of hepatic embolization/chemoembolization in companion animals has been described retrospectively in a few reports; these studies have included a small number of dogs and both bland embolization and chemoembolization were described [12][13][14]. In one study where tumor volumes were calculated, all dogs experienced a decrease in postoperative tumor volume [14]. More recently, 2 prospective studies have described the use of drug-eluting bead transarterial chemoembolization (DEB-TACE) in dogs, and the outcomes associated with beads containing cisplatin [15] and doxorubicin [16], respectively, were reported.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs

et al. 2022

View full text Add to dashboard Cite

In dogs with non-resectable hepatic neoplasia, treatment options are limited. The objectives of this study were to describe the use of a novel drug-eluting embolic microsphere containing paclitaxel for use during transarterial chemoembolization (TACE), to compare results of liver-specific owner questionnaires and tumor volume pre- and post-TACE, and to measure systemic paclitaxel concentration post-TACE. Client-owned dogs with non-resectable hepatic neoplasia were prospectively enrolled. All owners completed questionnaires validated for the assessment of subjective outcomes in dogs with cancer before the TACE procedure and approximately 4 weeks after the TACE procedure. A CT scan was performed before TACE and 1 month after TACE; results were compared. Blood samples were obtained at specified time points post-TACE to determine systemic paclitaxel concentrations. Seven dogs (median weight: 8.9 kg; range, 4.3–31 kg) were enrolled. TACE was successfully performed in all dogs, and no intra-procedural complications were encountered. Questionnaire scores improved significantly post-TACE. Among the 6 dogs for which full data were available, median pre-TACE tumor volume was 390 cc (range 152–1,484; interquartile range 231–1,139) and median post-TACE tumor volume was 203 cc (range 98–889; interquartile range 151–369), which was significantly (P = .028) lower. All 6 dogs had a reduction in volume at the post-TACE measurement. Mean percent change in tumor volume was -45.6% (95%CI -58.6 to -32.6%). The mean plasma paclitaxel concentration in canine blood peaked at 4 days post-TACE procedure and was 25.7 ng/mL (range = 3.09–110 ng/mL) Median survival time was 629 days (95%CI 18 to upper limit not reached). The use of a novel paclitaxel-eluting microsphere in this cohort of dogs successfully decreased tumor volume significantly after TACE and improved clinical signs. Future investigation into the use of TACE and other similar therapies is warranted due to the promising outcomes noted in this cohort.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In veterinary medicine, TACE has not been established as a standard treatment modality despite it being described to be feasible and to have some positive therapeutic effects on canine tumours including nonresectable hepatic carcinomas (Weisse et al 2002, Cave et al 2003, Oishi et al 2019, Rogatko et al 2021, osteosarcoma (Weisse et al 2002) and soft tissue fibrosarcoma/ sarcoma (Sun et al 2002, de La Villeon et al 2011. The present report suggests TACE might also have a benefit on QOL in canine RCCs with pulmonary metastases.…”

Section: Discussionmentioning

confidence: 99%

“…For TACE, vascular access procedure was performed with reference to previous reports (Weisse et al 2002, Oishi et al 2019. Briefly, a small incision was made in the right femoral triangle to isolate the right femoral artery, and a 5-French, 3-cm long introducer sheath (Medikit Super Sheath; Medikit Co. Ltd., Tokyo, Japan) was positioned in the right femoral artery.…”

Section: Transarterial Chemoembolisationmentioning

confidence: 99%

Transarterial chemoembolisation for palliative treatment of renal cell carcinoma in two dogs with pulmonary metastasis

Kimata

Ishigaki

Tamura

et al. 2022

J of Small Animal Practice

View full text Add to dashboard Cite

Two dogs with anorexia and rapid weight loss were referred to our hospital due to a right renal mass and several pulmonary nodules. Both dogs underwent needle core biopsy of the mass, followed by transarterial chemoembolisation of the renal mass. A catheter was inserted from the femoral artery and advanced into the right renal artery. A suspension of carboplatin (100 mg/m 2 ) and equivalent lipiodol was administered via the inserted multipurpose catheter. Immediately after, under fluoroscopic guidance, pulse injections of small amounts of gelatin particles (diameter 1 mm) dissolved in iohexol were administered until complete embolisation of the renal artery. Histopathologic diagnosis was renal cell carcinoma in both dogs. Clinical signs improved for 134 and 358 days after transarterial chemoembolisation. In addition, postoperative radiographs demonstrated a decrease in the tumour size. The dogs died 215 and 525 days after the initial evaluation, respectively. As a palliative treatment, transarterial chemoembolisation might help reduce the tumour volume and improve the quality of life in dogs with renal cell carcinoma and distant metastases.

show abstract

“…Drug-eluting bead transarterial chemoembolization (DEB-TACE) is expected to function both as a drug delivery system and an embolic agent for feeding artery occlusion. Bland TAE in healthy beagles was reported to be safe [21,23] and possibly effective in veterinary practice [22]. Reports of TACE performed in dogs are rare [2,32], and to the best of our knowledge, no reports have been published on DEB-TACE performed in dogs.…”

Section: Introductionmentioning

confidence: 98%

Effect of drug-eluting bead transarterial chemoembolization loaded with cisplatin on normal dogs

et al. 2022

View full text Add to dashboard Cite

Transcatheter arterial embolization (TAE) and transcatheter arterial chemoembolization (TACE) are standard treatments for advanced hepatocellular carcinoma (HCC) and particularly for unresectable tumors or liver metastases in humans. However, reports on TACE used in veterinary medicine are few. This study aimed to evaluate the feasibility and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE). We performed DEB-TACE in four clinically normal dogs and pharmacokinetically compared the results against hepatic arterial infusion (HAI) of cisplatin in two dogs. Drug-eluting beads (DEB) loaded with cisplatin were injected through a microcatheter for selective embolization of the left hepatic artery. After embolization, computed tomography (CT) images and histological examination findings were obtained during a 4-week observation period. Serum platinum concentrations were measured to evaluate cisplatin after each procedure. Biochemical analysis was performed during a 12-week observation period.Embolization was successful in all dogs, and there were no clinically apparent abnormalities. Embolization was confirmed up to 4 weeks after DEB-TACE in two of the four dogs and up to 1 week in the other two dogs using postoperative CT images.Cisplatin was not detected in peripheral veins in all dogs after DEB-TACE, but it was detected in trace amounts after HAI. DEB-TACE using cisplatin was safe and well tolerated by normal dogs. DEB-TACE may be useful in terms of determining systemic toxicity and drug concentration within tumors.

show abstract

Transcatheter arterial embolisation in four dogs with hepatocellular carcinoma

Cited by 7 publications

References 16 publications

Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs

Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs

Transarterial chemoembolisation for palliative treatment of renal cell carcinoma in two dogs with pulmonary metastasis

Effect of drug-eluting bead transarterial chemoembolization loaded with cisplatin on normal dogs

Contact Info

Product

Resources

About